Perfuze is focused on advancing stroke treatment through innovative catheter technology that enhances vessel access and improves the potential for complete clot ingestion. Their approach addresses a significant unmet clinical need, as current thrombectomy methods often result in suboptimal outcomes for patients. The company emphasizes the limitations of existing technologies, such as stentrievers and small bore aspiration devices, which can lead to complications like clot fragmentation and multiple passes during procedures. These challenges contribute to extended procedure times and increased risks of vessel trauma, highlighting the necessity for a more effective solution.

The core of Perfuze's technology lies in its advanced superbore aspiration system, which aims to simplify the process of accessing and removing clots in occluded brain arteries. By facilitating a first-pass effect, their system seeks to achieve complete reperfusion in a single attempt, significantly improving patient outcomes. This innovative approach is designed to overcome the limitations of current devices, which often require multiple attempts and can result in less than optimal revascularization rates. Perfuze's commitment to enhancing stroke treatment reflects their goal of providing a straightforward and repeatable solution that can lead to better clinical results for patients suffering from ischemic strokes.

Ireland

Developing innovative catheter technology to treat acute ischemic stroke, providing superior clinical outcomes in shorter procedural times.

Perfuze

Company Details